MARKET

PLRX

PLRX

Pliant Therapeutics, Inc.
NASDAQ
1.235
+0.005
+0.41%
Opening 13:26 12/15 EST
OPEN
1.230
PREV CLOSE
1.230
HIGH
1.250
LOW
1.190
VOLUME
704.08K
TURNOVER
--
52 WEEK HIGH
15.27
52 WEEK LOW
1.100
MARKET CAP
75.89M
P/E (TTM)
-0.4306
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PLRX last week (1208-1212)?
Weekly Report · 8h ago
Pliant Therapeutics Announces Departure of Chief Medical Officer
TipRanks · 6d ago
PLIANT THERAPEUTICS INC - TERMINATES CMO ÉRIC LEFEBVRE EFFECTIVE DECEMBER 15 - SEC FILING
Reuters · 6d ago
Pliant Therapeutics Announces Departure of Chief Medical Officer Éric Lefebvre
Reuters · 6d ago
Weekly Report: what happened at PLRX last week (1201-1205)?
Weekly Report · 12/08 10:19
Analysts Offer Insights on Healthcare Companies: Pliant Therapeutics (PLRX), uniQure (QURE) and Medtronic (MDT)
TipRanks · 12/04 23:50
Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors
Benzinga · 12/04 18:53
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 12/04 17:05
More
About PLRX
Pliant Therapeutics, Inc. is a late-stage biotechnology company, which is focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.

Webull offers Pliant Therapeutics Inc stock information, including NASDAQ: PLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PLRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PLRX stock methods without spending real money on the virtual paper trading platform.